Arkolith/Insider Trading/CYTH/Form 4

Fine N Scott

Chief Executive Officer, DirectorCyclo Therapeutics, Inc. (CYTH) · full profile →Form 4 · filed Oct 23, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 20, 2023Option exercise(X)299K$0.71$213K744K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 20, 2023Buy(P)329K——329K
Oct 20, 2023Option exercise(X)299K$0.13$39K0

Transaction Codes

X
Exercise of in-the-money derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-23-028700) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML